Q-omics provides the consensus-scored SERPINA7 profile across patient tissues and cancer cell-line models. SERPINA7 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SERPINA7 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, SERPINA7 protein abundance shows 31,818 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, COAD, and BRCA as cancer lineages where SERPINA7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SERPINA7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SERPINA7 survival associations across molecular data types. SERPINA7 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (6) and mass-spec protein abundance (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SERPINA7 RNA expression–survival associations across cancer types. High SERPINA7 expression shows unfavorable associations in KICH and HNSC, but favorable associations in KIRC, SCLC, LIHC and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SERPINA7 RNA expression.
This table summarizes SERPINA7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 12. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SERPINA7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SERPINA7 shows lower tumor expression in KICH, CHOL and LIHC and higher tumor expression in COAD, LUAD and THCA. The COAD box plot shows higher SERPINA7 RNA expression in tumor versus normal tissue (log2 FC = +0.580, t-test p < 0.001).
This table shows molecular features associated with SERPINA7 in patient tissues and cancer cell lines. In patient samples, SERPINA7 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, SERPINA7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LUNG_NSCLC_LUAD.
